New study tracks brain and energy side effects of prostate cancer meds
NCT ID NCT07181122
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 102 men with metastatic hormone-sensitive prostate cancer who are taking standard drugs (abiraterone, apalutamide, enzalutamide, or darolutamide) plus hormone therapy. Researchers will check thinking skills, fatigue, mood, and sleep at the start, 3 months, and 6 months using simple questionnaires. The goal is to see how these treatments affect daily life and mental function in the real world.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Androgen receptor pathway inhibitors (abiraterone, apalutamide, enzalutamide, darolutamide)
What this could lead to
If successful, this study could help doctors understand how these drugs affect thinking, energy, and mood, leading to better support for patients.
What could go wrong
This is an observational study, not a treatment trial. It only measures outcomes without testing a new therapy, so it won't directly improve treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Etlik City Hospital Medical Oncology Department
RECRUITINGAnkara, Yenimahalle, 06270, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gazi University Medical Oncology Department
RECRUITINGAnkara, Çankaya, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••